
Yale is one of eighteen Type 1 Diabetes TrialNet International Clinical Centers at the forefront of type 1 diabetes research. Led by our Clinical Center Director and Principal Investigator, Kevan Herold, MD, the TrialNet team at Yale is dedicated to preventing type 1 diabetes and stopping disease progression by preserving insulin production before and after diagnosis.
Our Team

Dr. Jennifer Sherr
was determined to become a pediatric endocrinologist since the time of her diagnosis with Type 1 Diabetes. While she always wanted to care for those with T1D, her eyes were opened to the meaningful impact that clinical research has. Dr. Sherr has since been devoted to clinical research over the past 15 years. She serves as a Professor in the Department of Pediatrics at Yale and focuses on methods, including new technologies and therapeutics, to improve the lives of all people living with diabetes.

Alfonso Galderisi, MD, PhD
is a pediatric endocrinologist who completed his training in Italy at the University of Padova. At the university of Padova he conducted the first trial using continuous glucose monitoring to adjust glucose intakes of very preterm infants, followed by a large Cooperative European Study aimed to identify the effects of early glucose changes on neonatal brain.
During his research fellowship at Yale University in 2016 he worked on the role of the incretins as determinants of beta cell function in children with obesity. More recently, by the use of metabolic modelling, his research focused on the physiopathology of insulin sensitivity and secretion in the early stages of T1D. His research areas include the physiology of insulin secretion and sensitivity in children with T1D and T2D and the early neonatal glucose metabolism. His research had been supported by the European Commission (while he was assistant professor of Pediatrics in Italy) and by the Juvenile Diabetes Research Foundation.

Kate Weyman, APRN, FNP-C, CDCES
is a Nurse Practitioner and Certified Diabetes Care and Education Specialist in the Pediatric Endocrinology Section at the Yale School of Medicine and is a clinical instructor for the Yale School of Nursing. Kate earned her undergraduate degree in nursing from the University of Vermont. She completed her Master's degree at the Yale School of Nursing where she became a Family Nurse Practitioner. After working for several years in family practice, Kate specialized in endocrinology and obtained her Certified Diabetes Care and Education Specialist certification. She has a special interest in clinical research related to Type 1 diabetes and has been working with the Yale diabetes research team for nearly 15 years. Kate enjoys the capacity that clinical research affords her to work closely with children and their families as we strive for improved lives and outcomes for those living with type 1.
Eileen Tichy, PA
is a physician assistant who specializes in treating children with type 1 diabetes. She also sees patients with obesity and hyperlipidemia, a condition of having very high levels of fats (lipids) in the blood.
“I was a dietician before becoming a physician assistant and I’ve always been interested in how nutrition can affect wellness,” Tichy says. “Diabetes is a very difficult disorder and we try to help lighten the burden patients may feel.”
One of the responses Tichy sees in patients after a diagnosis is a sense of feeling overwhelmed. “They might say, ‘I’m never going to be able to do this,’ and they ask question after question,” Tichy says. “But I always tell them, ‘You will be an expert—and your parents will be experts—in diabetes.” She encourages patients to talk with her and also to nurture a sense of self-trust.
“We have a great team that provides lots of support and ideas for patients,”

Marcia DeSousa, BA
Clinical Research AssociateRegional Affiliates
Affiliates provide opportunities for people who do not live near Yale. The affiliate sites listed below work with Yale to offer convenient participation in our research programs.
Research Studies
If you have a relative with T1D, you may be eligible for risk screening that can detect the early stages of T1D years before symptoms appear. More
Depending on your risk screening results, you may be eligible for monitoring. We’ll monitor you for disease progression and let you know if you become eligible for a study. More
TrialNet is testing a low dose of the immunotherapy drug anti-thymocyte globulin (ATG) to see if it can delay or prevent type 1 diabetes (T1D) in people ages 6 to 34 who have a 50% risk of clinical diagnosis (Stage 3) within 2 years. Risk is defined by having two or more autoantibodies and abnormal blood sugar (Stage 2), plus at least one high-risk marker (based on test results). In an earlier TrialNet study for people newly diagnosed with T1D, low-dose ATG preserved insulin production and improved blood sugar control for 2 years. Details
If you are diagnosed with T1D while participating in one of our prevention studies, we’re still here for you. You can continue to receive personal monitoring while helping us learn more. More
TrialNet is testing the safety of a new treatment, NNC0361-0041, in adults diagnosed with type 1 diabetes (T1D) in the past 48 months. This is a Phase 1 study, which means it is the first time this treatment is being tested for safety in people. If this study results in no safety concerns, we plan to conduct a larger study to see if this same treatment can slow down or stop T1D in people at high risk, before clinical diagnosis. More
TrialNet researchers are testing two different treatments – abrocitinib and ritlecitinib – to see if either or both can preserve insulin production in people (ages 12-35) newly diagnosed with type 1 diabetes (Stage 3 T1D). Abrocitinib and ritlecitinib are in a new class of autoimmune treatments called Janus kinase (JAK) inhibitors. Details
TrialNet is testing rituximab-pvvr and abatacept in people (ages 8-45) who were newly diagnosed with type 1 diabetes (T1D) to learn if using both treatments, one after the other, maintains the body’s ability to make insulin. By adding abatacept after rituximab-pvvr, researchers predict more people will experience prolonged beta cell function during and possibly after treatment. Details